Overview
Vilon is a synthetic dipeptide (Lys-Glu) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a vascular cytoprotective peptide. Research demonstrates it reduces vascular endothelial cell aging, suppresses excessive collagen synthesis, and modulates the renin-angiotensin system. Long-term animal studies show improved vascular function and survival; it is often studied as part of peptide longevity protocols.
Routes of Administration
Standard research protocol
Research Profile
Mechanism of Action
Pharmacokinetics
Key Research Findings
Side Effects & Safety
Research Search Terms
Links open PubMed searches for peer-reviewed studies on this peptide.
Frequently Asked Questions
Vilon is a synthetic dipeptide (Lys-Glu) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a vascular cytoprotective peptide. Research demonstrates it reduces vascular endothelial cell aging, suppresses excessive collagen synthesis, and modulates the renin-angiotensin system. Long-term animal studies show improved vascular function and survival; it is often studied as part of peptide longevity protocols.
The reported half-life of Vilon is Very short; longer-term epigenetic effects proposed. Half-life refers to the time required for the plasma concentration to decrease by half through metabolic clearance.
In research settings, Vilon is typically administered via: subcutaneous. Route selection affects onset, bioavailability, and duration of action.
Vilon is currently at the Preclinical research — studied in cell cultures and animal models, with no approved human clinical trials. stage.
Vilon profiles on Peptide United are for research and educational purposes only. This compound is not approved for human therapeutic use unless specifically noted. Always consult a qualified healthcare professional.
Related Compounds